PCDAmpl, a new antigen at the interface of the embryonic collecting duct epithelium and the nephrogenic mesenchyme

P CDAmpl, a new antigen at the interface of the embryonic collecting duct epithelium and the nephrogenic mesenchyme. In the neonatal rabbit kidney nephrogenesis is not yet terminated. The ampullar collecting duct epithelium acts as an inducer that generates the nephron anlagen, however, to date the morphogenic mechanisms involved are unknown. A presupposition for successful nephron induction is the close tissue interaction between the basal aspect of the ampullar collecting duct epithelium and the surrounding mesenchyme. To gain new insights in this area we raised monoclonal antibodies (mabs), to identify specific structures localized at the tissue interface. With the generated mab CDAmpl we found an intensive immunohistochemical reaction between the basal aspect of the ampullar collecting duct epithelium and the mesenchyme. The label was most concentrated at the ampullar tip and continuously decreased in the shaft region. In the maturing collecting duct of the neonatal kidney and in the adult renal collecting duct no immunohistochemical reaction was found. The binding pattern of mab CDAmpl is different from that of all known collecting duct cell markers and from antibodies against known basement membrane compounds such as laminin or collagen type IV. Under in vitro conditions immunoreactivity with mab CDAmpl was obtained using embryonic collecting duct epithelia and perfusion culture. The antigen was present in specimens treated with Iscove's modified Dulbecco's Medium (IMDM) containing 10% fetal bovine serum. Omittance of serum or hormonal treatment with aldosterone, insulin or vitamin D3 led to the disappearance of the newly detected antigen, while characteristics of the differentiated collecting duct cells were up-regulated. We conclude that the expression of P CDAmpl is a characteristic feature of the embryonic parts of the collecting duct epithelium. It may play a pivotal role during nephron induction

Out of sight but not out of harm’s way: human disturbance reduces reproductive success of a cavity-nesting seabird

While negative effects of human disturbance on animals living above the ground have been widely reported, few studies have considered effects on animals occupying cavities or burrows underground. It is generally assumed that, in the absence of direct visual contact, such species are less vulnerable to disturbance. Seabird colonies can support large populations of burrow- and cavity-nesting species and attract increasing numbers of tourists. We investigated the potential effects of recreational disturbance on the reproductive behaviour of the European storm petrel <i>Hydrobates pelagicus</i>, a nocturnally-active cavity-nesting seabird. Reproductive phenology and outcome of nests subject to high and low levels of visitor pressure were recorded in two consecutive years. Hatching success did not differ between disturbance levels, but overall nestling mortality was significantly higher in areas exposed to high visitor pressure. Although visitor numbers were consistent throughout the season, the magnitude and rate of a seasonal decline in productivity were significantly greater in nests subject to high disturbance. This study presents good evidence that, even when humans do not pose a direct mortality risk, animals may perceive them as a predation risk. This has implications for the conservation and management of a diverse range of burrow- and cavity-dwelling animals. Despite this reduction in individual fitness, overall colony productivity was reduced by ≤1.6% compared with that expected in the absence of visitors. While the colony-level consequences at the site in question may be considered minor, conservation managers must evaluate the trade-off between potential costs and benefits of public access on a site- and species-specific basis

Free Collisions in a Microgravity Many-Particle Experiment. I. Dust Aggregate Sticking at Low Velocities

Over the past years the processes involved in the growth of planetesimals have extensively been studied in the laboratory. Based on these experiments, a dust-aggregate collision model was developed upon which computer simulations were based to evaluate how big protoplanetary dust aggregates can grow and to analyze which kinds of collisions are relevant in the solar nebula and are worth further studies in the laboratory. The sticking threshold velocity of millimeter-sized dust aggregates is such a critical value that had so far only theoretically been derived, as the relevant velocities could not be reached in the laboratory. We developed a microgravity experiment that allows us for the first time to study free collisions of mm-sized dust aggregates down to velocities of ~0.1 cm/s to assess this part of the protoplanetary dust evolution model. Here, we present the results of 125 free collisions between dust aggregates of 0.5 to 2 mm diameter. Seven collisions with velocities between 0.2 and 3 cm/s led to sticking, suggesting a transition from perfect sticking to perfect bouncing with a certain sticking probability instead of a sharp velocity threshold. We developed a model to explain the physical processes involved in dust-aggregate sticking, derived dynamic material properties of the dust aggregates from the results of the collisions, and deduced the velocity below which aggregates always stick. For millimeter-sized porous dust aggregates this velocity is 8e-5 m/s.Comment: accepted by Icaru

Evaluating the provision of flexible learning for children at risk of primary school dropout in Malawi

Communities in Malawi selected 15 children deemed "at-risk" - predominantly orphans - in Class 6 of each of 20 intervention schools to receive learning materials, support from the community and a school "buddy." An experimental evaluation found that dropout was reduced by 45% across intervention schools compared to 20 control schools. The program had spillover effects, indirectly reducing dropout among older pupils in the class not deemed at-risk. These findings imply that age, and not orphanhood, was the main indicator of dropout risk and that when targeting criteria are considered carefully, flexible learning programs can reduce dropout substantially among vulnerable children. (C) 2014 Elsevier Ltd. All rights reserved

The future of Arctic sea-ice biogeochemistry and ice-associated ecosystems

The Arctic sea-ice-scape is rapidly transforming. Increasing light penetration will initiate earlier seasonal primary production. This earlier growing season may be accompanied by an increase in ice algae and phytoplankton biomass, augmenting the emission of dimethylsulfide and capture of carbon dioxide. Secondary production may also increase on the shelves, although the loss of sea ice exacerbates the demise of sea-ice fauna, endemic fish and megafauna. Sea-ice loss may also deliver more methane to the atmosphere, but warmer ice may release fewer halogens, resulting in fewer ozone depletion events. The net changes in carbon drawdown are still highly uncertain. Despite large uncertainties in these assessments, we expect disruptive changes that warrant intensified long-term observations and modelling efforts

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Microchip illustration (image)

http://deepblue.lib.umich.edu/bitstream/2027.42/61122/1/1704.pd